Group One Trading’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-735,300
| Closed | -$15.8M | – | 7758 |
|
|
2026
Q1 | $15.8M | Buy |
735,300
+670,000
| +1,026% | +$9.44M | 0.03% | 601 |
|
|
2025
Q4 | $609K | Buy |
65,300
+60,900
| +1,384% | +$509K | ﹤0.01% | 3314 |
|
|
2025
Q3 | $31K | Buy |
4,400
+1,200
| +38% | +$8.26K | ﹤0.01% | 6343 |
|
|
2025
Q2 | $20.8K | Buy |
3,200
+900
| +39% | +$6.19K | ﹤0.01% | 6241 |
|
|
2025
Q1 | $18.2K | Sell |
2,300
-4,800
| -68% | -$51.7K | ﹤0.01% | 5880 |
|
|
2024
Q4 | $90K | Sell |
7,100
-2,100
| -23% | -$29.2K | ﹤0.01% | 4611 |
|
|
2024
Q3 | $128K | Sell |
9,200
-39,300
| -81% | -$561K | ﹤0.01% | 3978 |
|
|
2024
Q2 | $668K | Buy |
48,500
+29,500
| +155% | +$432K | ﹤0.01% | 2315 |
|
|
2024
Q1 | $314K | Sell |
19,000
-45,300
| -70% | -$678K | ﹤0.01% | 3176 |
|
|
2023
Q4 | $939K | Buy |
64,300
+53,500
| +495% | +$649K | ﹤0.01% | 2506 |
|
|
2023
Q3 | $133K | Sell |
10,800
-29,600
| -73% | -$386K | ﹤0.01% | 4192 |
|
|
2023
Q2 | $482K | Buy |
40,400
+22,800
| +130% | +$298K | ﹤0.01% | 3068 |
|
|
2023
Q1 | $235K | Sell |
17,600
-28,700
| -62% | -$561K | ﹤0.01% | 3519 |
|
|
2022
Q4 | $996K | Buy |
46,300
+46,000
| +15,333% | +$943K | ﹤0.01% | 2408 |
|
|
2022
Q3 | $6K | Sell |
300
-2,700
| -90% | -$57.4K | ﹤0.01% | 6740 |
|
|
2022
Q2 | $54K | Buy |
+3,000
| New | +$31K | ﹤0.01% | 5484 |
|
Other funds holding DAWN
Group One Trading's DAWN Position: Q1 2026 in Review
Group One Trading sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 253,143 shares — an estimated $3.57M sold.
Group One Trading first reported a position in DAWN in Q3 2022 and held it in 8 quarters. The position peaked at $2.36M in Q4 2025. 208 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.
- Group One Trading reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Group One Trading sold 253,143 Day One Biopharmaceuticals shares in Q1 2026, an estimated $3.57M.
- Group One Trading first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 8 quarters.
- Group One Trading's Day One Biopharmaceuticals position peaked at $2.36M in Q4 2025.
- 208 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.